On July 13, 2022, the Brazilian federal health regulatory agency (Anvisa) granted emergency use of CoronaVac (Sinovac Biotech) to protect children between the ages 3 and 5 from SARS-CoV-2 based on a re-evaluation of clinical trial research from China,1 Chile2,3 and Brazil.4 This is a promising development as 41,395 children in this age group have been hospitalized for Severe Acute Respiratory Infection, SARI, (4470 COVID-confirmed), and 450 have died (144 COVID-confirmed) since the onset of the uncontrolled and preventable pandemic until the 22nd epidemiological week (epi week) of 2022 (see Appendix 1). Relative to 2019, the risk of SARI hospitalization in 2021 was 4.7 higher, and deaths have increased by 2 in this age group.
A rede de pesquisa solidária foi formada para elevar o padrão, calibrar o foco e aperfeiçoar a qualidade das políticas públicas do governo federal, dos governos estaduais e municipais que procuram atuar em meio à crise da COVID-19 para salvar vidas.
